Another string to your bow: machine learning prediction of the pharmacokinetic properties of small molecules

被引:5
作者
Bassani, Davide [1 ,2 ]
Parrott, Neil John [1 ]
Manevski, Nenad [1 ]
Zhang, Jitao David [1 ,2 ]
机构
[1] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Pharmaceut Res & Early Dev, Basel, Switzerland
[2] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Pharmaceut Sci, Pharm Res & Early Dev, Grenzacherstr, CH-4070 Basel, Switzerland
关键词
Drug discovery; pharmacokinetics; ADME; machine learning; PBPK; IVIVE; REVERSE TRANSLATION; MODELS; ADME; CLASSIFICATION; PBPK; PHARMACODYNAMICS; BIOAVAILABILITY; EXTRAPOLATION; OPPORTUNITIES; PERFORMANCE;
D O I
10.1080/17460441.2024.2348157
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionPrediction of pharmacokinetic (PK) properties is crucial for drug discovery and development. Machine-learning (ML) models, which use statistical pattern recognition to learn correlations between input features (such as chemical structures) and target variables (such as PK parameters), are being increasingly used for this purpose. To embed ML models for PK prediction into workflows and to guide future development, a solid understanding of their applicability, advantages, limitations, and synergies with other approaches is necessary.Areas coveredThis narrative review discusses the design and application of ML models to predict PK parameters of small molecules, especially in light of established approaches including in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) models. The authors illustrate scenarios in which the three approaches are used and emphasize how they enhance and complement each other. In particular, they highlight achievements, the state of the art and potentials of applying machine learning for PK prediction through a comphrehensive literature review.Expert opinionML models, when carefully crafted, regularly updated, and appropriately used, empower users to prioritize molecules with favorable PK properties. Informed practitioners can leverage these models to improve the efficiency of drug discovery and development process.
引用
收藏
页码:683 / 698
页数:16
相关论文
共 139 条
  • [1] Adachi K, 2022, BIOL PHARM BULL, V45, P1812, DOI 10.1248/bpb.b22-00502
  • [2] [Anonymous], REV USE 2 SPECIES RE
  • [3] [Anonymous], 2024, STARDROP SMALL MOL D
  • [4] Geometric deep learning on molecular representations
    Atz, Kenneth
    Grisoni, Francesca
    Schneider, Gisbert
    [J]. NATURE MACHINE INTELLIGENCE, 2021, 3 (12) : 1023 - 1032
  • [5] An Introduction to Machine Learning
    Badillo, Solveig
    Banfai, Balazs
    Birzele, Fabian
    Davydov, Iakov I.
    Hutchinson, Lucy
    Kam-Thong, Tony
    Siebourg-Polster, Juliane
    Steiert, Bernhard
    Zhang, Jitao David
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (04) : 871 - 885
  • [6] SuperCYPsPred-a web server for the prediction of cytochrome activity
    Banerjee, Priyanka
    Dunkel, Mathias
    Kemmler, Emanuel
    Preissner, Robert
    [J]. NUCLEIC ACIDS RESEARCH, 2020, 48 (W1) : W580 - W585
  • [7] Federated Learning in Computational Toxicology: An Industrial Perspective on the Effiris Hackathon
    Bassani, Davide
    Brigo, Alessandro
    Andrews-Morger, Andrea
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2023, 36 (09) : 1503 - 1517
  • [8] Past, Present, and Future Perspectives on Computer-Aided Drug Design Methodologies
    Bassani, Davide
    Moro, Stefano
    [J]. MOLECULES, 2023, 28 (09):
  • [9] endo-1-Phenylborneol as a novel, alternative chiral auxiliary for the aza-Diels-Alder reaction
    Bassani, Marco
    Scarso, Alessandro
    Drago, Maria
    Zambon, Alfonso
    Fabris, Fabrizio
    [J]. TETRAHEDRON LETTERS, 2020, 61 (31)
  • [10] Classification of Breast Cancer Resistant Protein (BCRP) Inhibitors and Non-Inhibitors Using Machine Learning Approaches
    Belekar, Vilas
    Lingineni, Karthik
    Garg, Prabha
    [J]. COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2015, 18 (05) : 476 - 485